Essential Partners’s Standard BioTools LAB Stock Holding History

Essential Partners’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,049	Closed	-$863	–	2926
2026 Q2	$863	Sell	1,049 -1,623	-61%	-$1.53K	﹤0.01%	2301
2026 Q1	$2.46K	Buy	2,672 +1,108	+71%	+$1.34K	﹤0.01%	1914
2025 Q4	$2K	Sell	1,564 -314	-17%	-$422	﹤0.01%	1798
2025 Q3	$2.44K	Hold	1,878	–	–	﹤0.01%	1726
2025 Q2	$2.25K	Buy	+1,878	New	+$2.08K	﹤0.01%	1281

Other funds holding LAB

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's LAB Position: Q3 2026 in Review

Essential Partners sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 1,049 shares — an estimated $863 sold.

Essential Partners first reported a position in LAB in Q2 2025 and held it in 5 quarters. The position peaked at $2.46K in Q1 2026. 3 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

Essential Partners reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
Essential Partners sold 1,049 Standard BioTools shares in Q3 2026, an estimated $863.
Essential Partners first reported a position in Standard BioTools in Q2 2025 and held it in 5 quarters.
Essential Partners's Standard BioTools position peaked at $2.46K in Q1 2026.
3 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.